News | Computed Tomography (CT) | April 26, 2016

New SCOT-HEART substudy shows coronary CT angiography cut MI risk in half compared to usual care

coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT

April 26, 2016 — The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA) leads to a more appropriate and effective selection of invasive coronary angiography for patients with suspected angina due to coronary heart disease. The use of CCTA also contributed to greater use of preventive therapies that led to a 50 percent reduction in risk for fatal and non-fatal myocardial infarction when compared to usual care, largely including stress testing.

The SCOT-HEART (Scottish COmputed Tomography of the HEART) trial demonstrated that CCTA markedly clarified the diagnosis for patients with suspected angina due to coronary heart disease. However, whether the CCTA-guided changes in diagnosis led to appropriate improvements in invasive coronary angiography and initiation of preventive treatments, and whether these changes could be attributable to an improvement in clinical outcome, had not been explored.

"SCOT-HEART has shown for the first time that CT coronary angiography can be used to reduce mortality in patients with suspected coronary heart disease. We showed that computed tomography improved the certainty of diagnosis, changed the prescription of preventative therapies and led to more appropriate use of invasive coronary angiography," said lead author Michelle C. Williams, M.D., MBChB, of the British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, U.K. "This resulted in the halving of fatal and non-fatal myocardial infarction after these changes in management were implemented. With SCOT-HEART we have moved beyond studies of diagnostic accuracy, and this study will certainly change practice."

"With this seminal analysis, CCTA has moved from a diagnostic test with unparalleled accuracy and significant prognostic information, to a test that can effectively guide therapeutic decision making," said Society of Cardiovascular Computed Tomography (SCCT) President Jonathon Leipsic, M.D., FSCCT. "The ability to help guide treatment strategies that reduce hard events will inevitably disrupt traditional care pathways."

Commenting on this study, SCCT President-Elect Leslee Shaw, Ph.D., FSCCT noted that "new findings conclusively demonstrate that CCTA is by far one of the key components to guide accurate diagnosis of and effective treatment for coronary artery disease (CAD). These findings will provide a new approach to diagnosis and treatment of CAD. Although requiring future validation, this analysis suggests that optimal improvements in patient outcomes can best be facilitated by CCTA."

The potential implications of this study on patient management following CTA are profound, according to Todd Villines, M.D., FSCCT, chair of the SCCT Education Committee. He noted that "the identification of both non-obstructive and obstructive (potentially flow-limiting) coronary artery disease is a tremendous advantage of coronary CTA. These findings demonstrate that disease burden on CTA, including non-obstructive disease, leads to important therapeutic changes that significantly reduce a patient's risk of suffering a first heart attack."

In an accompanying editorial, SCCT Past President James K. Min, M.D., FSCCT, professor of radiology at Weill Cornell Medical College and director of the Dalio Institute of Cardiovascular Imaging at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, spoke to the implications of these results. "This secondary analysis of SCOT-HEART is the highest-quality evidence to date for the comparative benefit of CCTA over standard-of-care approaches...In aggregate, these studies suggest that not only may CCTA be considered a reasonable alternative to stress testing for initial diagnostic CAD evaluation, but it may actually be preferred," he said.

For more information: www.scct.org


Related Content

News | PET-CT

June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research ...

Time June 19, 2025
arrow
News | Lung Imaging

April, 15, 2025 — Optellum has entered an agreement with Bristol Myers Squibb to leverage AI in early diagnosis and ...

Time April 17, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | SPECT Imaging

Feb. 5, 2025 — Serac Healthcare Ltd., a clinical radiopharmaceutical company developing an innovative molecular imaging ...

Time February 05, 2025
arrow
News | Computed Tomography (CT)

Dec. 3, 2024 — During RSNA '24, GE HealthCare announced the 510(k) submission to the U.S. Food and Drug Administration ...

Time December 18, 2024
arrow
News | SPECT Imaging

Dec. 2, 2024 — GE HealthCare has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing ...

Time December 05, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
Subscribe Now